“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.

The phase 3 ENVISION trial met its primary end point by demonstrating a 79.6% complete response rate at 3 months following the first instillation of the therapy.

"The scale of that linkage and the manner with which we were able to do it is really exciting and opens the door for a lot of future discovery," says Michael S. Leapman, MD, MHS.

Overall, 15/16 patients had a true positive scan based on confirmatory imaging and/or biopsy, equating to a PPV of 93.75%.

The TALAPRO-2 study authors noted that the use of androgen receptor (AR)–targeted therapy in clinical practice has increased considerably in recent years. How might prior use of AR-targeted therapy ...

Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations. Safety profiles of PARP inhibitors were consistent ...

"Over a third of Americans actually use some kind of what we term complementary or alternative medicine approach," says Raevti Bole, MD.

Lifestyle modifications, including yoga, hypnosis, and nutraceuticals, are increasingly used in BPH management, reflecting a trend towards integrating alternative medicine with traditional treatments.

The study is a large, multi-center, independently funded cohort series on Peyronie's disease treatment satisfaction. Patients who underpredict their penile curvature report higher satisfaction ...

PRP is popular for Peyronie disease due to its availability and safety, using patients' own biological factors. Limited data exist on PRP's efficacy for Peyronie disease, with studies showing no ...

The NRG-GU011 trial investigates relugolix plus SBRT versus SBRT alone in PET-oligometastatic prostate cancer. ORIOLE and STOMP studies indicate SBRT can delay recurrence without early ADT in some ...

The NDA submission is supported by data from a single-arm, phase 3 trial of leuprolide mesylate administered as 2 injections, 3 months apart.